Overview

Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma

Status:
Recruiting

Trial end date:
2020-10-01

Target enrollment:

Participant gender:

Summary

The main treatments for non-Hodgkin's lymphoma are surgery, radiotherapy, chemotherapy, and bone marrow transplantation. Neutropenia is the most common and serious complication of most chemotherapy. This study is a multi-center, open-label, single-arm clinical study to evaluate the efficacy and safety of jinyouli in preventing neutropenia in patients with non Hodgkin's lymphoma after chemotherapy.

Phase:

N/A

Details

Lead Sponsor:

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Collaborator:

Hebei Medical University Fourth Hospital